Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALSAM-2: Phase 3 study of KarXT for acute manic episodes in bipolar I disorder
CTR20263918Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline in bipolar I disorder, sponsored by Bristol Myers Squibb. Started Jun 2025; status: active.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on CTR20263918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263918.